Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Marc HumbertVallerie McLaughlinJ Simon R GibbsMardi Gomberg-MaitlandMarius M HoeperIoana R PrestonRogério de SouzaAaron B WaxmanHossein Ardeschir GhofraniPilar Escribano-SubiasJeremy FeldmanGisela MeyerI David MontaniKaren M OlssonSolaiappan ManimaranJanethe de Oliveira PenaDavid B BadeschPublished in: The European respiratory journal (2022)
These results support the longer-term safety and durability of clinical benefit of sotatercept for pulmonary arterial hypertension.